US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NervGen Pharma Corp.

1.76

-0.1500-7.85%

Volume:1.05M

Turnover:1.88M

Market Cap:190.08M

PE:-3.16

High:1.92

Open:1.92

Low:1.73

Close:1.91

52wk High:6.30

52wk Low:1.58

Shares:108.00M

Float Shares:95.39M

Volume Ratio:2.29

T/O Rate:1.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.5570

EPS(LYR):-0.4448

ROE:-757.48%

ROA:-37.70%

PB:15.65

PE(LYR):-3.96

Loading ...

Overview Company News Filings

NervGen Q1 FY26 net loss narrows to C$1.68 million

NervGen Pharma Corp expected to post a loss of 8 cents a share - Earnings Preview

NervGen Pharma (NGEN) Gets a Buy from Stifel Nicolaus

NervGen Pharma Initiated at Buy by HC Wainwright & Co.

NervGen Pharma appoints Keith Vendola as CFO

NervGen Pharma Strengthens Leadership Team With Appointment of Keith Vendola as Chief Financial Officer

THOMSON REUTERS

HC Wainwright Initiates Coverage on NervGen Pharma With Buy Rating, $18 Price Target

MT Newswires Live

NervGen Pharma to present at Bloom Burton Healthcare Investor Conference

NervGen Pharma price target raised to $12 from $10 at Maxim

BUZZ-NervGen rises after FDA backs late-stage study to test drug for spinal cord injury

NervGen wins FDA alignment for Phase 3 NVG-291 trial in chronic tetraplegia

NervGen Pharma Corp - to Conclude Enrollment in Phase 1B/2a Connect Sci Subacute Tetraplegia and Unblind Data

THOMSON REUTERS

NervGen Pharma Corp - Restore Study Initiation on-Track for Mid-2026

THOMSON REUTERS

NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on Restore, a Phase 3 Registrational Study of Nvg-291 for Chronic Tetraplegia

THOMSON REUTERS

NervGen FY25 net loss widens to $44.1 million; cash and investments climb to $22 million

BRIEF-Nervgen Pharma Reports Full Year 2025 Financial Results And Provides Business Updates

Press Release: NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

Calendar of U.S. Earnings Expected in the Week Ahead

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/NGEN/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NGEN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGEN\",,,,,undefined,":{"symbol":"NGEN","market":"US","secType":"STK","nameCN":"NervGen Pharma Corp.","latestPrice":1.76,"timestamp":1790884800000,"preClose":1.91,"halted":0,"volume":1051255,"delay":0,"changeRate":-0.07853403141361252,"floatShares":95391200,"shares":108000000,"eps":-0.557,"marketStatus":"Pre-Mkt","change":-0.15,"latestTime":"10-02 04:03:50 EDT","open":1.92,"high":1.92,"low":1.7301,"amount":1875599.0261364998,"amplitude":0.099424,"askPrice":2.81,"askSize":200,"bidPrice":0.7164,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.557,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1790947800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":1.76,"postHourTrading":{"tag":"盘后","latestPrice":1.8,"preClose":1.76,"latestTime":"19:50 EDT","volume":92884,"amount":163932.31,"timestamp":1790898631747,"change":0.04,"changeRate":0.022727,"amplitude":0.12358},"volumeRatio":2.2907502802909985,"impliedVol":0.0812,"impliedVolPercentile":0.2914},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGEN\",,,,,undefined,":{"symbol":"NGEN","floatShares":95391200,"roa":"-37.70%","roe":"-757.48%","lyrEps":-0.444846,"volumeRatio":2.290748,"shares":108000000,"dividePrice":0,"high":1.92,"amplitude":0.099424,"preClose":1.91,"low":1.7301,"week52Low":1.58,"pbRate":"15.65","week52High":6.3,"institutionHeld":0,"latestPrice":1.76,"committee":-0.333333,"eps":-0.557,"divideRate":0,"volume":1051255,"delay":0,"ttmEps":-0.557,"open":1.92,"prevYearClose":5.6,"prevWeekClose":1.94,"prevMonthClose":1.91,"prevQuarterClose":1.91,"fiveDayClose":2.02,"twentyDayClose":2.33,"sixtyDayClose":1.85},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NGEN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"NGEN","fiscalQuarterEnding":"2026/06","expectedEps":-0.09,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"pre","actualEps":-0.37},{"market":"US","date":"2026-05-15","symbol":"NGEN","fiscalQuarterEnding":"2026/03","expectedEps":-0.07,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778817600000,"reportTimeType":"post","actualEps":-0.09},{"date":"2026-03-31","symbol":"NGEN","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774944000000,"name":null,"time":"Pre-MKt","dateTimestamp":1774929600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NGEN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NGEN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.875,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.875,"analysts":8,"updateTime":1784001600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NGEN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NGEN","date":"2026-09-30","current":-3.159785,"percent":0.961111,"low":-25.148356,"twenty":-17.005665,"median":-9.17019,"eighty":-5.866178,"high":-4.008234,"avg":-10.794315,"sd":5.756838,"marketCap":206443455},"quantilePoints":[{"date":"2026-01-09","current":-25.148356,"twenty":-24.98651,"median":-24.743741,"eighty":-24.500973,"marketCap":463798962.95},{"date":"2026-01-16","current":-23.484013,"twenty":-24.651705,"median":-24.262661,"eighty":-23.546305,"marketCap":432253265.53},{"date":"2026-01-23","current":-22.238177,"twenty":-24.339127,"median":-23.484013,"eighty":-22.456198,"marketCap":412101315.23},{"date":"2026-01-30","current":-17.441707,"twenty":-24.262661,"median":-22.611928,"eighty":-20.307131,"marketCap":329508465.32},{"date":"2026-02-06","current":-16.382746,"twenty":-23.795472,"median":-22.238177,"eighty":-17.908896,"marketCap":306238051.42},{"date":"2026-02-13","current":-17.441707,"twenty":-23.484013,"median":-19.886661,"eighty":-17.285978,"marketCap":327197651.85},{"date":"2026-02-20","current":-18.220355,"twenty":-23.359429,"median":-18.282647,"eighty":-17.285978,"marketCap":340388899.6},{"date":"2026-02-27","current":-17.753166,"twenty":-22.879782,"median":-18.03348,"eighty":-17.410561,"marketCap":331850071.27},{"date":"2026-03-06","current":-17.223686,"twenty":-22.51849,"median":-17.893323,"eighty":-17.27352,"marketCap":321208516.98},{"date":"2026-03-13","current":-16.382746,"twenty":-22.306698,"median":-17.753166,"eighty":-16.993207,"marketCap":307553178.63},{"date":"2026-03-20","current":-16.957011,"twenty":-22.250635,"median":-17.753166,"eighty":-16.888553,"marketCap":316207550},{"date":"2026-03-27","current":-15.785094,"twenty":-21.714925,"median":-17.597437,"eighty":-16.837477,"marketCap":291516280},{"date":"2026-04-02","current":-18.89617,"twenty":-20.942507,"median":-17.535145,"eighty":-16.702393,"marketCap":347270760},{"date":"2026-04-10","current":-10.676925,"twenty":-19.970755,"median":-17.441707,"eighty":-16.494872,"marketCap":340718966},{"date":"2026-04-17","current":-10.464421,"twenty":-19.238183,"median":-17.254832,"eighty":-16.110604,"marketCap":336672423},{"date":"2026-04-24","current":-9.863583,"twenty":-18.837636,"median":-17.005665,"eighty":-12.953446,"marketCap":318058323},{"date":"2026-05-01","current":-9.064424,"twenty":-18.587877,"median":-16.950192,"eighty":-10.62677,"marketCap":293779061},{"date":"2026-05-08","current":-9.632569,"twenty":-18.344939,"median":-16.86331,"eighty":-10.287304,"marketCap":311583853},{"date":"2026-05-15","current":-9.34654,"twenty":-18.295105,"median":-16.834362,"eighty":-10.043494,"marketCap":300253531},{"date":"2026-05-22","current":-9.812417,"twenty":-18.145605,"median":-16.66306,"eighty":-9.800918,"marketCap":297825605},{"date":"2026-05-29","current":-7.287863,"twenty":-18.008563,"median":-16.66306,"eighty":-9.72533,"marketCap":220902522},{"date":"2026-06-05","current":-7.091826,"twenty":-17.902667,"median":-16.382746,"eighty":-9.634252,"marketCap":213468303},{"date":"2026-06-12","current":-6.717699,"twenty":-17.87775,"median":-16.216296,"eighty":-9.423447,"marketCap":200723927},{"date":"2026-06-18","current":-7.855923,"twenty":-17.87775,"median":-15.872071,"eighty":-9.364073,"marketCap":232584867},{"date":"2026-06-26","current":-6.880017,"twenty":-17.753166,"median":-13.39003,"eighty":-9.064424,"marketCap":202847989},{"date":"2026-07-02","current":-7.524736,"twenty":-17.753166,"median":-10.756935,"eighty":-7.674051,"marketCap":221964554},{"date":"2026-07-10","current":-6.687968,"twenty":-17.753166,"median":-10.600843,"eighty":-7.470839,"marketCap":197537832},{"date":"2026-07-17","current":-5.950494,"twenty":-17.703333,"median":-10.394273,"eighty":-7.2635,"marketCap":177359237},{"date":"2026-07-24","current":-5.990968,"twenty":-17.616125,"median":-10.19196,"eighty":-7.15871,"marketCap":177890252},{"date":"2026-07-31","current":-5.701372,"twenty":-17.597437,"median":-10.084942,"eighty":-7.057391,"marketCap":170260212},{"date":"2026-08-07","current":-6.137986,"twenty":-17.522687,"median":-9.917992,"eighty":-6.810664,"marketCap":183029728},{"date":"2026-08-14","current":-6.239509,"twenty":-17.454165,"median":-9.793252,"eighty":-6.730479,"marketCap":187286234},{"date":"2026-08-21","current":-4.207016,"twenty":-17.441707,"median":-9.728074,"eighty":-6.591693,"marketCap":189239834},{"date":"2026-08-28","current":-5.61745,"twenty":-17.34827,"median":-9.659831,"eighty":-6.31363,"marketCap":251065348},{"date":"2026-09-04","current":-5.551208,"twenty":-17.285978,"median":-9.555453,"eighty":-6.177212,"marketCap":249452508},{"date":"2026-09-11","current":-5.179874,"twenty":-17.261061,"median":-9.448244,"eighty":-6.142393,"marketCap":232248887},{"date":"2026-09-18","current":-5.512013,"twenty":-17.186311,"median":-9.401978,"eighty":-6.005849,"marketCap":244076376},{"date":"2026-09-25","current":-4.959579,"twenty":-17.080415,"median":-9.355306,"eighty":-5.930873,"marketCap":217195718},{"date":"2026-09-30","current":-4.730282,"twenty":-17.005665,"median":-9.17019,"eighty":-5.866178,"marketCap":206443455}],"updateTime":1790928230711},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NGEN\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635030458","title":"NervGen Q1 FY26 net loss narrows to C$1.68 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635030458","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635030458?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:35","pubTimestamp":1778877310,"startTime":"0","endTime":"0","summary":"NervGen Pharma posted a net loss of CAD 1.68 million for the three months ended March 31, 2026, narrowing from CAD 3.95 million a year earlier.Research and development expense rose to CAD 4.86 million, while general and administrative costs slipped to CAD 2.67 million.Unrealized gain on warrant derivative increased to CAD 5.72 million, helping cut the warrant derivative liability to CAD 9.35 million at quarter-end.Cash and cash equivalents fell to CAD 16.56 million as of March 31, 2026, from CAD 22.07 million at end-2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NervGen Pharma Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL4XDnCL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634428279","title":"NervGen Pharma Corp  expected to post a loss of 8 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634428279","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634428279?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:41","pubTimestamp":1778506865,"startTime":"0","endTime":"0","summary":"NervGen Pharma Corp  expected to post a loss of8cents a share - Earnings Preview NervGen Pharma Corp NGEN.OQ NGEN.O is expected to  report resultson May 13 (estimated) for the period ending March 31 2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O1H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630358527","title":"NervGen Pharma (NGEN) Gets a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2630358527","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630358527?lang=en_us&edition=fundamental","pubTime":"2026-04-28 22:35","pubTimestamp":1777386920,"startTime":"0","endTime":"0","summary":"In a report released today, Justin Keywood from Stifel Nicolaus maintained a Buy rating on NervGen Pharma, with a price target of $6.00. Keywood co...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/nervgen-pharma-ngen-gets-a-buy-from-stifel-nicolaus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/nervgen-pharma-ngen-gets-a-buy-from-stifel-nicolaus-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","BK4007","NGEN","SF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630064395","title":"NervGen Pharma Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2630064395","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630064395?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:48","pubTimestamp":1777290480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NGEN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 27, 2026 07:48 ET (11:48 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630953193","title":"NervGen Pharma appoints Keith Vendola as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2630953193","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630953193?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:32","pubTimestamp":1777289566,"startTime":"0","endTime":"0","summary":"NervGen Pharma appointed Keith Vendola as chief financial officer, effective immediately.Vendola will lead financial strategy, capital markets activity, financial planning, corporate development, and strategic initiatives.He joins from Wugen, where he served as CFO.Vendola previously served as CFO of IO Biotech, leading the company through its IPO.Earlier roles included CFO and chief strategy officer at Rezolute, plus chief of staff to CEO and vice president of competitive strategy and investor relations at Coherus BioSciences.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL7Tx2Kd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4112","SG9999014039.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4007","SG9999014005.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2T93.GBP","IOBT","SG9999014013.SGD","NDAQ","BK4585","NGEN","LU2095319765.USD","BK4588","BK4139","IE00BN0W2W23.USD","LU0314104364.USD","BK4535","CHRS","IE00BN0W2V16.EUR","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630930993","title":"NervGen Pharma Strengthens Leadership Team With Appointment of Keith Vendola as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2630930993","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630930993?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:30","pubTimestamp":1777289400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nTUA2HRM33:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630393285","title":"HC Wainwright Initiates Coverage on NervGen Pharma With Buy Rating, $18 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2630393285","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630393285?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:21","pubTimestamp":1777288871,"startTime":"0","endTime":"0","summary":"NervGen Pharma Corp. (NGEN) has an average rating of Buy and mean price target of $10.67, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627303954","title":"NervGen Pharma to present at Bloom Burton Healthcare Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2627303954","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627303954?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:45","pubTimestamp":1776080739,"startTime":"0","endTime":"0","summary":"NervGen executives scheduled to join H.C. Wainwright HCW@Home virtual fireside chat April 15, 2026.Bloom Burton Healthcare Investor Conference presentation set for April 22, 2026 in Toronto.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL5Qzzxk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","NDAQ","LU2210150020.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4588","SG9999014005.SGD","IE00BN0W2W23.USD","BK4007","SG9999014021.USD","NGEN","BK4585","LU2095319765.USD","SG9999014039.USD","IE00B3QW5Z07.USD","LU0314104364.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626392458","title":"NervGen Pharma price target raised to $12 from $10 at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2626392458","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626392458?lang=en_us&edition=fundamental","pubTime":"2026-04-09 03:20","pubTimestamp":1775676016,"startTime":"0","endTime":"0","summary":"Maxim raised the firm’s price target on NervGen Pharma (NGEN) to $12 from $10 and keeps a Buy rating on the shares, citing alignment with the FDA o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-price-target-raised-to-12-from-10-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-price-target-raised-to-12-from-10-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGEN","BK4585","BK4588","LABU","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625195846","title":"BUZZ-NervGen rises after FDA backs late-stage study to test drug for spinal cord injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2625195846","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625195846?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:36","pubTimestamp":1775565370,"startTime":"0","endTime":"0","summary":"BUZZ-NervGen rises after FDA backs late-stage study to test drug for spinal cord injury** Shares of biotech firm NervGen Pharma NGEN.O rise 7% to $4.71 premarket** Co says the FDA agreed on the design of a late-stage study for its experimental drug for spinal cord injury, NVG-291,  that aims to improve hand movement in people with chronic paralysis of all four limbs** Co says the 16-week study in about 150 adults in the U.S. and Canada will test whether daily injections improve fine hand use versus placebo ** Says the FDA alignment follows earlier results showing better hand function, bladder control and less muscle stiffness in treated patients** Adds the trial is expected to start in mid-2026; NVG-291 already has FDA fast-track status** As of last close, stock down ~22% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nL4N40Q0UQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625937930","title":"NervGen wins FDA alignment for Phase 3 NVG-291 trial in chronic tetraplegia","url":"https://stock-news.laohu8.com/highlight/detail?id=2625937930","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625937930?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:38","pubTimestamp":1775561918,"startTime":"0","endTime":"0","summary":"NervGen reported FDA alignment on RESTORE, a Phase 3 registrational trial of NVG-291 in adults with chronic tetraplegia, with study start targeted for mid-2026.Phase 1b/2a CONNECT SCI results were already presented as support for Phase 3, showing NVG-291 improved hand function versus placebo and benefits persisted beyond dosing.Patient-reported outcomes in CONNECT SCI indicated more participants on NVG-291 felt meaningfully improved, supporting potential real-world impact on daily independence.RESTORE will enroll about 150 subjects across up to 60 sites in US and Canada, with an optional open-label extension designed to broaden access for placebo recipients.NervGen elected to stop enrollment in subacute tetraplegia cohort of CONNECT SCI and unblind available data to apply Phase 3 endpoint framework to a future study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, thi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL5BMp5Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625937302","title":"NervGen Pharma Corp - to Conclude Enrollment in Phase 1B/2a Connect Sci Subacute Tetraplegia and Unblind Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2625937302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625937302?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:30","pubTimestamp":1775561400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA4DFBKY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625373729","title":"NervGen Pharma Corp - Restore Study Initiation on-Track for Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625373729","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625373729?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:30","pubTimestamp":1775561400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA4DFBKY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625373089","title":"NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on Restore, a Phase 3 Registrational Study of Nvg-291 for Chronic Tetraplegia","url":"https://stock-news.laohu8.com/highlight/detail?id=2625373089","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625373089?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:30","pubTimestamp":1775561400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA4DFBKY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624555644","title":"NervGen FY25 net loss widens to $44.1 million; cash and investments climb to $22 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624555644","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624555644?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:36","pubTimestamp":1774993004,"startTime":"0","endTime":"0","summary":"NervGen posted a net loss of $44.1 million, or $0.61 per share.Non-cash items totaled $24.8 million within the annual loss.R&D expense fell to $13.9 million due to completion of chronic CONNECT SCI cohort and lower preclinical spending.G&A costs climbed to $11.2 million on higher legal and professional fees tied to Nasdaq listing.Cash and investments rose to $22.1 million; Phase 3 in chronic tetraplegia remains on track for mid-2026 with FDA regulatory update expected in early 2Q 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL39P81j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","SG9999014005.SGD","BK4585","SG9999014039.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","NDAQ","BK4007","LU2210150020.SGD","BK4112","SG9999014013.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","LU0314104364.USD","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623821525","title":"BRIEF-Nervgen Pharma Reports Full Year 2025 Financial Results And Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2623821525","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623821525?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:29","pubTimestamp":1774963776,"startTime":"0","endTime":"0","summary":"BRIEF-Nervgen Pharma Reports Full Year 2025 Financial Results And Provides Business UpdatesNervGen Pharma Corp NGEN.O:NERVGEN PHARMA REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATESSource text: ID:nGNX6jn2DNFurther company coverage: NGEN.O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA1CKGSD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623863765","title":"Press Release: NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2623863765","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623863765?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:46","pubTimestamp":1774957560,"startTime":"0","endTime":"0","summary":"-- Completed End-of-Phase 2 meeting with the FDA; Company expects to provide. a regulatory update in early 2Q 2026 and remains on track to initiate a. Phase 3 study in chronic tetraplegia in mid-2026.-- Company expects to present clinical data from independent, blinded. providing additional evidence with the potential to further support the. systemic biological effect of NVG-291, differentiating genuine neural. -- Company expects to expand NVG-291 into complementary clinical indications,as informed by established preclinical efficacy, with prioritization. supports the Company's emergence as a leader in the development of. \"2025 was a transformative year for NervGen, but more importantly the SCI community,\" said Adam Rogers, MD, President and Chief Executive Officer of NervGen. \"We've demonstrated the potential best-in-class profile of NVG-291 and its ability to meaningfully improve the lives of those with chronic tetraplegia in the CONNECT SCI study, and we continue to strengthen our u","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1892829315.USD","BK4192","BK4548","LU0266013472.USD","NGEN","LU1989771016.USD","LU1291159041.SGD","SCI","LU0077335932.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623315199","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2623315199","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623315199?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:00","pubTimestamp":1774864800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·INmune Bio Inc.                                 4Q      (.26)  4:05 PM. ·Dave & Buster                                   4Q       .39   4:05 PM. ·NIKE Class B                                     3Q       .29   4:15 PM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIRO","NKLR","AURA","BYND","CAG","LW","CRDL","FC","NGEN","MKC","KEEL","BEEM","PRPL","MKC.V","PVLA","BIRD","FDS","PENG","NMRA","PRGS","RH","BNZI","SGML","AIRJ","INV","PLAY","NCNO","INMB","PROP","NNOX","LNN","BHST","DMAC","NEOG","PHR","MSM","AYI","CALM","NKE","PVH","RNXT","AEHR","APOG","BITF","IMNN","SGMO","JILL","MAZE","BCAX","BTBT","ANGO"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":58,"code":"91000000","status":"200"}]}}